Dimerix Ltd
ASX:DXB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dimerix Ltd
Free Cash Flow
Dimerix Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dimerix Ltd
ASX:DXB
|
Free Cash Flow
AU$11.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Free Cash Flow
-$60.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Free Cash Flow
$2.5B
|
CAGR 3-Years
59%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Free Cash Flow
-AU$7.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Free Cash Flow
-AU$73.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Free Cash Flow
-AU$66.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-57%
|
|
Dimerix Ltd
Glance View
Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.
See Also
What is Dimerix Ltd's Free Cash Flow?
Free Cash Flow
11.4m
AUD
Based on the financial report for Dec 31, 2025, Dimerix Ltd's Free Cash Flow amounts to 11.4m AUD.
